Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

94
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
94
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

127
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
127
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

116
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
116
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

67
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
67
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

77
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
77
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. フィラミンc断片型によって引き起こされる心筋病の現象表現,自然史,およびリスク分層
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. フィラミンc断片型によって引き起こされる心筋病の現象表現,自然史,およびリスク分層

関連する実験動画

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

フィラミンC断片型によって引き起こされる心筋病の現象表現,自然史,およびリスク分層

Marta Gigli1, Davide Stolfo1,2, Sharon L Graw3

  • 1Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy (M.G., D.S., M.M., M.D.F., A.P., G.D.A., F.B., G.S.).

Circulation
|September 30, 2021

PubMed で要約を見る

まとめ
この要約は機械生成です。

フィラミンC断片化変種 (FLNCtv) は心律異常を引き起こす. この研究は,左心室機能不全の重度に関係なく,FLNCtvのキャリアは,心不全と不律の高いリスクに直面していることを示しています.

キーワード:
FLNCタンパク質,ヒト動脈動乱性右心房不形成症突然の心臓発作による死亡

さらに関連する動画

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.9K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.0K

関連する実験動画

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.9K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.0K

科学分野:

  • 心臓病科
  • 遺伝学
  • 分子生物学

背景:

  • フィラミンC断片化変種 (FLNCtv) は不律性心筋病と関連している.
  • FLNCtvのプレゼンテーション,自然史,リスクの階層化は十分に調査されていない.

研究 の 目的:

  • FLNCtvキャリアにおける耐火性心不全および生命を脅かす不律症のリスクプロファイルを開発する.
  • FLNCtvキャリアのマルチセンターコホートでの結果を分析する.

主な方法:

  • 10の医療センターから FLNCtv キャリアを特定した.
  • 死亡率,心臓移植,心室補助装置の移植を含む複合的なアウトカムを定義する臨床データとアウトカムデータをまとめました.
  • LMNAとDSP関連心律不全のコホートとの予後を比較した.

主要な成果:

  • 85人のFLNCtvキャリア (42歳±15歳,53%男性) は,拡張性および不律性心筋病を含む異質なフェノタイプを示した.
  • 61ヶ月の追跡期間中,22%が死亡率/心臓移植/LVAD,15%が非リズム死亡率/HT/LVAD,27%が突然の心臓死亡率/大心室不律を経験した.
  • FLNCtvキャリアは,LMNAとDSPキャリアと比較して,突然の心臓死亡/主要な心室不律の発生率を示した. 左心室放出分子は,D/HT/LVADリスクを予測した.
心不全
結果調査
予後について

結論:

  • FLNCtv 動脈動乱性心筋病は,第三次リファールされた患者で表型的に異なっています.
  • FLNCtvのキャリアは,生命を脅かす不律症の大きなリスクに直面します.
  • FLNCtv心筋病における不律のリスクは,左心房機能障害の重症度と直接相関しているとは見られない.